Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Recruiting now · Phase 2
Conditions studied: Medulloblastoma
In brief
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Key facts
- Study ID
- NCT05535166
- Run by
- St. Jude Children's Research Hospital
- People needed
- 130
- Starts
- 2022-12-20
- Expected to finish
- 2035-07-01
- Last updated by the study team
- 2026-02-12
Who can join
Age: any, up to 5. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Lucille Packard Children's Hospital Stanford — Palo Alto, California, United States (enrolling)
- Orlando Health Arnold Palmer Hospital for Children — Orlando, Florida, United States (enrolling)
- St. Joseph's Children's Hospital — Tampa, Florida, United States (enrolling)
- C.S. MOTT Children's Hospital, University of Michigan — Ann Arbor, Michigan, United States (enrolling)
- Children's Hospital and Clinics of Minnesota — Minneapolis, Minnesota, United States (enrolling)
- St. Jude Children's Research Hospital — Memphis, Tennessee, United States (enrolling)
- UT Southwestern Medical Center/Harold C Simmons Comprehensive Cancer Center — Dallas, Texas, United States (enrolling)
- Cook Children's Medical Center — Fort Worth, Texas, United States (enrolling)
- Texas Children's Hospital — Houston, Texas, United States (enrolling)
- Primary Children's Hospital — Salt Lake City, Utah, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.